Clinical Research Directory
Browse clinical research sites, groups, and studies.
Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery
Sponsor: Cairo University
Summary
Myopic shift remains a debilitating and unpredictable adverse event following pediatric cataract surgery. While research exploring peripheral myopic defocus for post-cataract surgery myopia prevention shows promising results, the use of multifocal intra-ocular lenses (IOLs) cannot be used liberally in countries with high disease burden and challenged economies due to high price and decreased availability. To date there are no studies evaluating the use of topical atropine for the management of myopic shift following pediatric cataract surgery. The investigators aim to explore the use of 0.05% topical atropine in the prevention and management of myopic shift following pediatric cataract surgery.
Official title: Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery: A Randomized Clinical Trial
Key Details
Gender
All
Age Range
1 Year - 7 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-02
Completion Date
2027-12
Last Updated
2026-01-23
Healthy Volunteers
No
Interventions
Atropine Eye drops
Atropine eye drops, 0.05%, will be given following IOL implantation for a period of 12 months.
Locations (1)
Cairo University
Cairo, Egypt